These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

307 related items for PubMed ID: 10591535

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamic of tolterodine.
    Brynne N, Dalén P, Alván G, Bertilsson L, Gabrielsson J.
    Clin Pharmacol Ther; 1998 May; 63(5):529-39. PubMed ID: 9630826
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Significant interaction between the nonprescription antihistamine diphenhydramine and the CYP2D6 substrate metoprolol in healthy men with high or low CYP2D6 activity.
    Hamelin BA, Bouayad A, Méthot J, Jobin J, Desgagnés P, Poirier P, Allaire J, Dumesnil J, Turgeon J.
    Clin Pharmacol Ther; 2000 May; 67(5):466-77. PubMed ID: 10824625
    [Abstract] [Full Text] [Related]

  • 7. Pharmacokinetic and pharmacodynamic interaction between mexiletine and propafenone in human beings.
    Labbé L, O'Hara G, Lefebvre M, Lessard E, Gilbert M, Adedoyin A, Champagne J, Hamelin B, Turgeon J.
    Clin Pharmacol Ther; 2000 Jul; 68(1):44-57. PubMed ID: 10945315
    [Abstract] [Full Text] [Related]

  • 8. Dihydrocodeine: a new opioid substrate for the polymorphic CYP2D6 in humans.
    Fromm MF, Hofmann U, Griese EU, Mikus G.
    Clin Pharmacol Ther; 1995 Oct; 58(4):374-82. PubMed ID: 7586928
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. The influence of CYP2D6 polymorphism on the antiarrhythmic efficacy of propafenone in patients with paroxysmal atrial fibrillation during 3 months propafenone prophylactic treatment.
    Jazwinska-Tarnawska E, Orzechowska-Juzwenko K, Niewinski P, Rzemislawska Z, Loboz-Grudzien K, Dmochowska-Perz M, Slawin J.
    Int J Clin Pharmacol Ther; 2001 Jul; 39(7):288-92. PubMed ID: 11471772
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Disposition of propafenone in a poor metabolizer of CYP2D6 with Gilbert's syndrome.
    Dilger K, Meisel P, Hofmann U, Eichelbaum M.
    Ther Drug Monit; 2000 Jun; 22(3):366-8. PubMed ID: 10850406
    [Abstract] [Full Text] [Related]

  • 14. CYP2D6 polymorphism is not crucial for the disposition of selegiline.
    Scheinin H, Anttila M, Dahl ML, Karnani H, Nyman L, Taavitsainen P, Pelkonen O, Bertilsson L.
    Clin Pharmacol Ther; 1998 Oct; 64(4):402-11. PubMed ID: 9797797
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Induction of CYP2D6 in pregnancy.
    Wadelius M, Darj E, Frenne G, Rane A.
    Clin Pharmacol Ther; 1997 Oct; 62(4):400-7. PubMed ID: 9357391
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Effect of CYP2D6 polymorphisms on the pharmacokinetics of propafenone and its two main metabolites.
    Rouini MR, Afshar M.
    Therapie; 2017 Jun; 72(3):373-382. PubMed ID: 28087064
    [Abstract] [Full Text] [Related]

  • 20. Pharmacokinetics and electrocardiographic effects of a new controlled-release form of flecainide acetate: comparison with the standard form and influence of the CYP2D6 polymorphism.
    Tennezé L, Tarral E, Ducloux N, Funck-Brentano C.
    Clin Pharmacol Ther; 2002 Aug; 72(2):112-22. PubMed ID: 12189358
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.